Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

RCT (n=83) evaluating safety and immunogenicity of rSARS-CoV-2 vaccine (NVX-CoV2373) in 5-μg and 25-μg doses, with or without Matrix-M1 adjuvant found that at 35 days, it appeared to be safe, and elicited immune responses that exceeded levels in Covid-19 convalescent serum.


New England Journal of Medicine